Acumen Pharmaceuticals (NASDAQ:ABOS) Issues Earnings Results

Acumen Pharmaceuticals (NASDAQ:ABOS) posted its quarterly earnings data on Tuesday. The company reported ($0.33) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.07, FiscalAI reports.

Here are the key takeaways from Acumen Pharmaceuticals’ conference call:

• Acumen said ALTITUDE-AD remains on track, with top-line Phase II results expected late in 2026 and enrollment/extension transitions proceeding smoothly. Management reiterated that the study is designed to test whether sabirnetug can deliver a differentiated effect by targeting toxic Abeta oligomers rather than amyloid plaques.
• The company highlighted a potentially favorable data package from ALTITUDE-AD, including the primary endpoint (iADRS) plus secondary efficacy, safety, ARIA, and biomarker readouts. Management said a “clear win” would likely require an efficacy signal around 30% slowing or better, along with a compelling risk-benefit profile versus approved anti-amyloid drugs.
• Acumen also emphasized progress in its enhanced brain delivery (EBD) program and said it expects to exercise its option to license two JCR Pharmaceuticals compounds in Q2 2026. The company continues to target an IND filing in mid-2027 and believes the platform could improve brain penetration, distribution, and enable subcutaneous dosing.
• The balance sheet ended the quarter at $128.4 million in cash and marketable securities, which management said should fund operations into early 2027. First-quarter operating results included $16.5 million of R&D expense, $4.7 million of G&A expense, and a $20.7 million net loss.
• Management said site feedback and operational execution on ALTITUDE-AD have been strong, including a relatively fast 10-month enrollment and improved screening using plasma p-tau217 to reduce unnecessary PET scans. They also noted continued physician and KOL interest in sabirnetug and the broader anti-amyloid market despite recent skepticism about the class.

Acumen Pharmaceuticals Stock Performance

Shares of ABOS stock traded down $0.08 during trading hours on Tuesday, reaching $2.50. The stock had a trading volume of 174,692 shares, compared to its average volume of 694,414. The company has a debt-to-equity ratio of 0.32, a current ratio of 4.07 and a quick ratio of 4.07. Acumen Pharmaceuticals has a twelve month low of $0.97 and a twelve month high of $3.60. The firm has a 50-day simple moving average of $2.77 and a 200-day simple moving average of $2.35. The firm has a market capitalization of $180.21 million, a PE ratio of -1.23 and a beta of 0.32.

Hedge Funds Weigh In On Acumen Pharmaceuticals

Several large investors have recently bought and sold shares of the stock. XTX Topco Ltd acquired a new position in Acumen Pharmaceuticals during the 4th quarter valued at about $105,000. Quadrature Capital Ltd acquired a new position in Acumen Pharmaceuticals during the 4th quarter valued at about $103,000. OMERS ADMINISTRATION Corp acquired a new position in Acumen Pharmaceuticals during the 4th quarter valued at about $47,000. Marshall Wace LLP acquired a new position in Acumen Pharmaceuticals during the 4th quarter valued at about $44,000. Finally, Dimensional Fund Advisors LP increased its stake in Acumen Pharmaceuticals by 12.7% during the 4th quarter. Dimensional Fund Advisors LP now owns 49,062 shares of the company’s stock valued at $104,000 after buying an additional 5,538 shares during the period. Institutional investors and hedge funds own 71.01% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on ABOS. Weiss Ratings restated a “sell (d-)” rating on shares of Acumen Pharmaceuticals in a research report on Wednesday, April 8th. BTIG Research reaffirmed a “buy” rating and issued a $8.00 price objective on shares of Acumen Pharmaceuticals in a report on Thursday, March 26th. Finally, Wall Street Zen raised shares of Acumen Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Sunday, March 29th. Three analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $6.67.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral small molecule therapies for neurodegenerative diseases. Leveraging a proprietary drug discovery platform that integrates chemoproteomics, high-throughput screening and computational chemistry, the company seeks to identify and optimize compounds that selectively modulate pathological protein aggregation. Its approach is designed to address the underlying biology of conditions such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis and related proteinopathies.

The company’s pipeline comprises multiple lead candidates at various stages of preclinical and early clinical development.